

Renata Ursu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7240112/publications.pdf>

Version: 2024-02-01

29
papers

1,297
citations

567281

15
h-index

501196

28
g-index

30
all docs

30
docs citations

30
times ranked

2243
citing authors

#	ARTICLE	IF	CITATIONS
1	Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life experience of the French Network. Bone Marrow Transplantation, 2022, 57, 966-974.	2.4	12
2	Predictive factors of human cytomegalovirus reactivation in newly diagnosed glioblastoma patients treated with chemoradiotherapy. Journal of NeuroVirology, 2021, 27, 94-100.	2.1	2
3	Descriptive and retrospective analysis of diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the pandemic. Neuro-Oncology Advances, 2021, 3, vtab078.	0.7	2
4	Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study. Journal of Neurology, 2021, 268, 2515-2522.	3.6	4
5	Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study. Neuro-Oncology, 2021, 23, 1569-1575.	1.2	20
6	Hypometabolism on brain FDG-PET as a marker for neurotoxicity after CAR T-cell therapy: A case report. Revue Neurologique, 2021, , .	1.5	2
7	SARS-CoV-2 infection in patients with primary central nervous system lymphoma. Journal of Neurology, 2021, 268, 3072-3080.	3.6	7
8	Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients. , 2020, 8, e001034.		20
9	Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). European Journal of Cancer, 2020, 141, 62-81.	2.8	122
10	Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases. Cancers, 2020, 12, 2635.	3.7	5
11	Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Scientific Reports, 2020, 10, 18997.	3.3	59
12	Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma a randomised multicentre trial (ASTER trial). An ANOCEF study. European Journal of Cancer, 2019, 109, 129-136.	2.8	13
13	Varicella Zoster Virus vasculopathy in a patient treated with immune checkpoint inhibitor for lung cancer. Revue Neurologique, 2019, 175, 95-97.	1.5	6
14	Assessing cognitive function in patients treated with immune checkpoint inhibitors: A feasibility study. Psycho-Oncology, 2018, 27, 1861-1864.	2.3	12
15	Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model. Journal of Neuro-Oncology, 2018, 136, 565-576.	2.9	47
16	Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. European Journal of Cancer, 2017, 73, 1-8.	2.8	397
17	Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma A phase II multicentric, randomised study. European Journal of Cancer, 2017, 73, 30-37.	2.8	68
18	Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?. Journal of Neuro-Oncology, 2017, 135, 285-297.	2.9	35

#	ARTICLE	IF	CITATIONS
19	Impact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients. Journal of Neurology, 2016, 263, 524-530.	3.6	19
20	Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma. European Journal of Neurology, 2015, 22, 1304-1309.	3.3	28
21	Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial. Cancer Science, 2015, 106, 1212-1218.	3.9	24
22	Evolution of the Karnosky Performance Status throughout life in glioblastoma patients. Journal of Neuro-Oncology, 2015, 122, 567-573.	2.9	39
23	Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial.. Journal of Clinical Oncology, 2013, 31, 3065-3065.	1.6	0
24	Superficial siderosis of the central nervous system: a rare cause of dementia with therapeutic consequences. Age and Ageing, 2012, 41, 275-277.	1.6	8
25	Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neuro-Oncology, 2012, 14, 491-495.	1.2	83
26	Immunotherapeutic Approach with Oligodeoxynucleotides Containing CpG Motifs (CpG-ODN) in Malignant Glioma. Advances in Experimental Medicine and Biology, 2012, 746, 95-108.	1.6	17
27	Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients. European Journal of Neurology, 2012, 19, 1337-1342.	3.3	35
28	Steroid requirements during radiotherapy for malignant gliomas. Journal of Neuro-Oncology, 2010, 100, 89-94.	2.9	29
29	Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro-Oncology, 2010, 12, 401-408.	1.2	180